Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Figure 3

Percentage of cytomegalovirus (CMV)-specific CD28neg CD4pos T cells from RA patients receiving anti-TNF treatments. Peripheral blood mononuclear cells (PBMCs) from CMV-seropositive patients were incubated with CMV Ags, and intracellular interferon (IFN)-γ production and CD28 expression were measured with flow cytometry, as indicated in Materials and Methods. Percentages of IFN-γ-producing CD28neg CD4pos T cells are represented according to the responder/nonresponder clinical status of patients.

Back to article page